Q-omics provides the consensus-scored STK32B profile across patient tissues and cancer cell-line models. STK32B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, STK32B is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, STK32B RNA expression shows 18,245 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where STK32B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STK32B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STK32B survival associations across molecular data types. STK32B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STK32B RNA expression–survival associations across cancer types. High STK32B expression shows unfavorable associations in UVM, BLCA, ACC and LIHC, but favorable associations in KIRC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for STK32B RNA expression.
This table summarizes STK32B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for STK32B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STK32B shows lower tumor expression in KICH, BLCA, STAD, THCA and COAD and higher tumor expression in HNSC. The KICH box plot shows higher STK32B RNA expression in normal versus tumor tissue (log2 FC = −3.846, t-test p < 0.001).
This table shows molecular features associated with STK32B in patient tissues and cancer cell lines. In patient samples, STK32B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, STK32B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SKIN.
